Literature DB >> 32443404

Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies.

Alexey Boyko1,2,3, Mikhail Melnikov1,2,4.   

Abstract

In the Russian Federation, multiple sclerosis prevalence rates vary from 10 to 80 cases per 100,000, depending on region and the nationality of the population. The main characteristics of multiple sclerosis epidemiology in the XX century in this big territory are: (1) steady increase in multiple sclerosis prevalence and incidence rates, maybe because of better diagnosis and treatment, but also changes in environmental/epigenetic risk profile and/or lifestyle factors; (2) increase of the female to male ratio, increase in multiple sclerosis incidence mainly in females; (3) appearance and increasing frequency of multiple sclerosis in ethnic groups, previously free of multiple sclerosis (Northern Tribes, Yakuts and others). The latest data show that in European Russia, the multiple sclerosis prevalence varies from 30 to 80 cases, in Siberia-from 20 to 70 cases, with steady increases, especially in women.

Entities:  

Keywords:  epidemiology; incidence; multiple sclerosis; prevalence

Year:  2020        PMID: 32443404     DOI: 10.3390/brainsci10050305

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  3 in total

1.  The Core of Gut Life: Firmicutes Profile in Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  Madina Kozhieva; Natalia Naumova; Tatiana Alikina; Alexey Boyko; Valentin Vlassov; Marsel R Kabilov
Journal:  Life (Basel)       Date:  2021-01-14

Review 2.  Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Authors:  Rongzeng Liu; Shushu Du; Lili Zhao; Sahil Jain; Kritika Sahay; Albert Rizvanov; Vera Lezhnyova; Timur Khaibullin; Ekaterina Martynova; Svetlana Khaiboullina; Manoj Baranwal
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

3.  Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?

Authors:  Mikhail Melnikov; Mikhail Pashenkov; Alexey Boyko
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.